20,949 research outputs found

    An Efficient Algorithm for Mining Frequent Sequence with Constraint Programming

    Full text link
    The main advantage of Constraint Programming (CP) approaches for sequential pattern mining (SPM) is their modularity, which includes the ability to add new constraints (regular expressions, length restrictions, etc). The current best CP approach for SPM uses a global constraint (module) that computes the projected database and enforces the minimum frequency; it does this with a filtering algorithm similar to the PrefixSpan method. However, the resulting system is not as scalable as some of the most advanced mining systems like Zaki's cSPADE. We show how, using techniques from both data mining and CP, one can use a generic constraint solver and yet outperform existing specialized systems. This is mainly due to two improvements in the module that computes the projected frequencies: first, computing the projected database can be sped up by pre-computing the positions at which an symbol can become unsupported by a sequence, thereby avoiding to scan the full sequence each time; and second by taking inspiration from the trailing used in CP solvers to devise a backtracking-aware data structure that allows fast incremental storing and restoring of the projected database. Detailed experiments show how this approach outperforms existing CP as well as specialized systems for SPM, and that the gain in efficiency translates directly into increased efficiency for other settings such as mining with regular expressions.Comment: frequent sequence mining, constraint programmin

    Electrostatics in a simple wormhole revisited

    Full text link
    The electrostatic potential generated by a point charge at rest in a simple static, spherically symmetric wormhole is given in the form of series of multipoles and in closed form. The general potential which is physically acceptable depends on a parameter due to the fact that the monopole solution is arbitrary. When the wormhole has Z2-symmetry, the potential is completely determined. The calculation of the electrostatic self-energy and of the self-force is performed in all cases considered.Comment: 16 pages, no figure

    Impact of Wind Penetration and HVDC Upgrades on Dynamic Performance of Future Grids

    No full text

    Considerations Toward Coordinated Control of DFIG-Based Wind Farms

    Get PDF

    Damping and Relative Mode-Shape Estimation in Near Real-Time Through Phasor Approach

    Get PDF

    Economic evaluation of ASCOT-BPLA: Antihypertensive treatment with an amlodipine-based regimen is cost-effective compared to an atenolol-based regimen

    Get PDF
    Copyright © 2010 BMJ Publishing Group Ltd & British Cardiovascular Society. Internal or personal use of this material is permitted. However, permission to reprint/republish this material must be obtained from the Publisher.Objective: To compare the cost effectiveness of an amlodipine-based strategy and an atenolol-based strategy in the treatment of hypertension in the UK and Sweden. Design: A prospective, randomised trial complemented with a Markov model to assess long-term costs and health effects. Setting: Primary care. Patients: Patients with moderate hypertension and three or more additional risk factors. Interventions: Amlodipine 5–10 mg with perindopril 4–8 mg added as needed or atenolol 50–100 mg with bendroflumethiazide 1.25–2.5 mg and potassium added as needed Main outcome measures: Cost per cardiovascular event and procedure avoided, and cost per quality-adjusted life-year gained. Results: In the UK, the cost to avoid one cardiovascular event or procedure would be €18 965, and the cost to gain one quality-adjusted life-year would be €21 875. The corresponding figures for Sweden were €13 210 and €16 856. Conclusions: Compared with the thresholds applied by NICE and in the Swedish National Board of Health and Welfare’s Guidelines for Cardiac Care, an amlodipine-based regimen is cost effective for the treatment of hypertension compared with an atenolol-based regimen in the population studied.The study was supported by the principal funding source, Pfizer, New York, USA
    • …
    corecore